Clinical Trials
4 trialsNCT05782361 2026-04-24
POTENT
Institute of Cancer Research, United Kingdom
Phase 1 Active not recruiting
NCT02864992 2026-04-13
VISION
EMD Serono
Phase 2 Active not recruiting
NCT06083857 2026-03-11
PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT03940703 2026-02-27
A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)
EMD Serono
Phase 2 Active not recruiting